XML 154 R97.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Principal alliances - Agreements on the commercialization of Beyfortus™ (nirsevimab, previously MEDI8897) in the US (Details) - EUR (€) € in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | ---
Jul. 31, 2023 | Nov. 30, 2022 | Mar. 31, 2017 | Sep. 30, 2019 | Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022
Disclosure of Principal Alliances [Line Items] |  |  |  |  |  |  |  |
Collaboration agreements, upfront payment |  |  |  | € 120 |  |  |  |
Other non-current liabilities | [1] |  |  |  |  | € 2,334 | € 2,340 | € 519
Antibodies Collaboration agreement | AstraZeneca |  |  |  |  |  |  |  |
Disclosure of Principal Alliances [Line Items] |  |  |  |  |  |  |  |
Collaboration agreements, development milestone payment |  |  |  |  | € 30 |  |  |
Collaboration agreements, regulatory milestone payment |  | € 65 | € 25 |  |  |  |  |
Commitments related to milestone payments for projects under collaboration agreements |  |  |  |  |  |  | 375 |
Accruals |  |  |  |  |  | 100 |  |
Collaboration Agreements, Amount Paid |  |  |  |  |  | 25 |  |
Collaboration Agreements, Amount Made |  |  |  |  |  | € 50 |  |
Intangible assets and goodwill |  |  |  |  |  |  | 1,600 |
Total financial liabilities measured at fair value |  |  |  |  |  |  | 1,600 |
Antibodies Collaboration agreement | AstraZeneca | Major territories |  |  |  |  |  |  |  |
Disclosure of Principal Alliances [Line Items] |  |  |  |  |  |  |  |
Percentage of profits arising from commercial operations |  |  |  |  |  | 5000.00% |  |
Antibodies Collaboration agreement | AstraZeneca | Other territories |  |  |  |  |  |  |  |
Disclosure of Principal Alliances [Line Items] |  |  |  |  |  |  |  |
Percentage of profits arising from commercial operations |  |  |  |  |  | 25.00% |  |
Antibodies Collaboration agreement | Swedish Orphan Biovitrum AB |  |  |  |  |  |  |  |
Disclosure of Principal Alliances [Line Items] |  |  |  |  |  |  |  |
Other non-current liabilities |  |  |  |  |  | € 2,007 |  |
Increase through remeasurement of financial liability |  |  |  |  |  | 291 | 541 |
Immuno-oncology collaboration agreement | Regeneron Pharmaceuticals, INC | Major Collaboration Agreement |  |  |  |  |  |  |  |
Disclosure of Principal Alliances [Line Items] |  |  |  |  |  |  |  |
Proceeds from collaboration agreements |  |  |  |  |  | € 117 | € 196 | € 952
[1] | (a)Includes derivative financial instruments: €121 million as of December 31, 2024, €164 million as of December 31, 2023, €232 million as of December 31, 2022. The figure as of December 31, 2024 includes €2,007 million for the liability in respect of royalties payable to Sobi on net sales of Beyfortus (nirsevimab) in the United States (see Note C.2.). Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is €1,140 million; the nominal value of payments estimated to be due after more than five years is €2,792 million.

X
- Definition The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 78 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_Accruals
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity’s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity’s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity’s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity’s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity’s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity’s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 7 -IssueDate 2023-01-01 -Paragraph 25 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_FinancialLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 55 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_IntangibleAssetsAndGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 55 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_OtherNoncurrentLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaboration Agreements, Amount Made + References No definition available. + Details
Name: | sny_CollaborationAgreementsAmountMade
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration Agreements, Amount Paid + References No definition available. + Details
Name: | sny_CollaborationAgreementsAmountPaid
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration Agreements, Development Milestone Payment + References No definition available. + Details
Name: | sny_CollaborationAgreementsDevelopmentMilestonePayment
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreements, Regulatory Milestone Payment + References No definition available. + Details
Name: | sny_CollaborationAgreementsRegulatoryMilestonePayment
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreements, Upfront Payment + References No definition available. + Details
Name: | sny_CollaborationAgreementsUpfrontPayment
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Commitments Related To Milestone Payments For Projects Under Collaboration Agreement + References No definition available. + Details
Name: | sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Disclosure of Principal Alliances [Line Items] + References No definition available. + Details
Name: | sny_DisclosureOfPrincipalAlliancesLineItems
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase (Decrease) Through Remeasurement, Other Non-Current Liabilities + References No definition available. + Details
Name: | sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage Of Profits Arising From Commercial Operations + References No definition available. + Details
Name: | sny_PercentageOfProfitsArisingFromCommercialOperations
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Proceeds From Collaboration Agreements + References No definition available. + Details
Name: | sny_ProceedsFromCollaborationAgreements
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_AstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=sny_MajorTerritoriesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=sny_OtherTerritoriesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_SwedishOrphanBiovitrumABMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_PrincipalAlliancesAxis=sny_ImmunoOncologyCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sny_MajorCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |